Psychedelic Drugs as Therapeutics: No Illusions About the Challenges

Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2018-04, Vol.103 (4), p.561-564
Main Authors: Sellers, Edward M., Leiderman, Deborah B.
Format: Article
Language:English
Subjects:
Drug Approval - methods
Drug Discovery - ethics
Drug Discovery - methods
Hallucinogens - pharmacology
Hallucinogens - therapeutic use
Humans
Mental Disorders - drug therapy
Patient Selection
Risk Evaluation and Mitigation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3
cites cdi_FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3
container_end_page 564
container_issue 4
container_start_page 561
container_title Clinical pharmacology and therapeutics
container_volume 103
creator Sellers, Edward M.
Leiderman, Deborah B.
description Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
doi_str_mv 10.1002/cpt.776
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cpt_776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQQBdRbK3iP5C9eZDU_ehust5K6kehaA_1HHY3s01k24RsQsm_N6XqzdMw8HjMPIRuKZlSQtijrdtpHMszNKaCs0gKLs7RmBCiIsW4HKGrEL6GdaaS5BKNWJJwyWI2Rot16G0BOfjS4kXTbQPWAW8KaHQNXVva8ITfK7z0vgtltQ94bqquxW0BOC2097DfQrhGF077ADc_c4I-X5436Vu0-nhdpvNVZDmNZWTyGVPKEeM4A0OVMUrAcKlylJiYa6WlEo5KlzijlSSQ2NxIKoArKfKZ4xN0f_LapgqhAZfVTbnTTZ9Rkh07ZEOHbOgwkHcnsu7MDvI_7vfxAXg4AYfSQ_-fJ0vXm6PuG8H-ZmE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychedelic Drugs as Therapeutics: No Illusions About the Challenges</title><source>Wiley</source><creator>Sellers, Edward M. ; Leiderman, Deborah B.</creator><creatorcontrib>Sellers, Edward M. ; Leiderman, Deborah B.</creatorcontrib><description>Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.776</identifier><identifier>PMID: 28836272</identifier><language>eng</language><publisher>United States</publisher><subject>Drug Approval - methods ; Drug Discovery - ethics ; Drug Discovery - methods ; Hallucinogens - pharmacology ; Hallucinogens - therapeutic use ; Humans ; Mental Disorders - drug therapy ; Patient Selection ; Risk Evaluation and Mitigation</subject><ispartof>Clinical pharmacology and therapeutics, 2018-04, Vol.103 (4), p.561-564</ispartof><rights>2017 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2017 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3</citedby><cites>FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.776$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.776$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28836272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sellers, Edward M.</creatorcontrib><creatorcontrib>Leiderman, Deborah B.</creatorcontrib><title>Psychedelic Drugs as Therapeutics: No Illusions About the Challenges</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.</description><subject>Drug Approval - methods</subject><subject>Drug Discovery - ethics</subject><subject>Drug Discovery - methods</subject><subject>Hallucinogens - pharmacology</subject><subject>Hallucinogens - therapeutic use</subject><subject>Humans</subject><subject>Mental Disorders - drug therapy</subject><subject>Patient Selection</subject><subject>Risk Evaluation and Mitigation</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kE1Lw0AQQBdRbK3iP5C9eZDU_ehust5K6kehaA_1HHY3s01k24RsQsm_N6XqzdMw8HjMPIRuKZlSQtijrdtpHMszNKaCs0gKLs7RmBCiIsW4HKGrEL6GdaaS5BKNWJJwyWI2Rot16G0BOfjS4kXTbQPWAW8KaHQNXVva8ITfK7z0vgtltQ94bqquxW0BOC2097DfQrhGF077ADc_c4I-X5436Vu0-nhdpvNVZDmNZWTyGVPKEeM4A0OVMUrAcKlylJiYa6WlEo5KlzijlSSQ2NxIKoArKfKZ4xN0f_LapgqhAZfVTbnTTZ9Rkh07ZEOHbOgwkHcnsu7MDvI_7vfxAXg4AYfSQ_-fJ0vXm6PuG8H-ZmE</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Sellers, Edward M.</creator><creator>Leiderman, Deborah B.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201804</creationdate><title>Psychedelic Drugs as Therapeutics: No Illusions About the Challenges</title><author>Sellers, Edward M. ; Leiderman, Deborah B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Drug Approval - methods</topic><topic>Drug Discovery - ethics</topic><topic>Drug Discovery - methods</topic><topic>Hallucinogens - pharmacology</topic><topic>Hallucinogens - therapeutic use</topic><topic>Humans</topic><topic>Mental Disorders - drug therapy</topic><topic>Patient Selection</topic><topic>Risk Evaluation and Mitigation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sellers, Edward M.</creatorcontrib><creatorcontrib>Leiderman, Deborah B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sellers, Edward M.</au><au>Leiderman, Deborah B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychedelic Drugs as Therapeutics: No Illusions About the Challenges</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2018-04</date><risdate>2018</risdate><volume>103</volume><issue>4</issue><spage>561</spage><epage>564</epage><pages>561-564</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.</abstract><cop>United States</cop><pmid>28836272</pmid><doi>10.1002/cpt.776</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2018-04, Vol.103 (4), p.561-564
issn 0009-9236
1532-6535
language eng
recordid cdi_crossref_primary_10_1002_cpt_776
source Wiley
subjects Drug Approval - methods
Drug Discovery - ethics
Drug Discovery - methods
Hallucinogens - pharmacology
Hallucinogens - therapeutic use
Humans
Mental Disorders - drug therapy
Patient Selection
Risk Evaluation and Mitigation
title Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T20%3A22%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychedelic%20Drugs%20as%20Therapeutics:%20No%20Illusions%20About%20the%20Challenges&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Sellers,%20Edward%20M.&rft.date=2018-04&rft.volume=103&rft.issue=4&rft.spage=561&rft.epage=564&rft.pages=561-564&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.776&rft_dat=%3Cwiley_cross%3ECPT776%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3176-bd4299f0bf32eb19bb95e5359f10b73a9a695f16f8fba960e8cdb615e3965d4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28836272&rfr_iscdi=true